4.5 Review

Functional characteristics and research trends of PDE11A in human diseases

Journal

MOLECULAR MEDICINE REPORTS
Volume 26, Issue 4, Pages -

Publisher

SPANDIDOS PUBL LTD
DOI: 10.3892/mmr.2022.12814

Keywords

phosphodiesterase 11A; glioblastoma; phosphodiesterase 11A mutation; cancer biomarker; cAMP; cGMP signaling; Alzheimer's disease; bipolar disorder; sperm productivity and mobility

Ask authors/readers for more resources

cAMP and cGMP are important secondary messengers involved in cell regulation and metabolism. cAMP is converted by adenylyl cyclase and activates protein kinase A, while PDEs hydrolyze cAMP and cGMP. PDE11A, the 11th member of the PDE family, is associated with genetic conditions and plays a role in diseases such as Cushing syndrome and glioblastoma.
cAMP and cGMP are important secondary messengers involved in cell regulation and metabolism driven by the G protein-coupled receptor. cAMP is converted via adenylyl cyclase (AC) and activates protein kinase A to phosphorylate intracellular proteins that mediate specific responses. cAMP signaling serves a role at multiple steps in tumorigenesis. The level of cAMP is increased in association with cancer cell formation through activation of AC-stimulatory G protein by mutation. Phosphodiesterases (PDEs) hydrolyze cAMP and cGMP to AMP and GMP. PDEs are composed of 11 families, and each can hydrolyze cAMP and cGMP or both cAMP and cGMP. PDEs perform various roles depending on their location and expression site, and are involved in several diseases, including male erectile dysfunction, pulmonary hypertension, Alzheimer's disease and schizophrenia. PDE11A is the 11th member of the PDE family and is characterized by four splice variants with varying tissue expression and N-terminal regulatory regions. Among tissues, the expression of PDE11A was highest in the prostate, and it was also expressed in hepatic skeletal muscle, pituitary, pancreas and kidney. PDE11A is the first PDE associated with an adrenocortical tumor associated genetic condition. In several studies, three PDE11A mutations have been reported in patients with Cushing syndrome with primary pigmented nodular adrenocortical disease or isolated micronodular adrenocortical disease without other genetic defects. It has been reported that an increase in PDE11A expression affects the proliferation of glioblastoma and worsens patient prognosis. The present mini-review summarizes the location of PDE11A expression, the impact of structural differences and disease relevance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available